SPR Therapeutics Inc., a leader in neurostimulation technology for pain, announced that the U.S. Food and Drug Administration cleared the company’s SPRINT endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems.
NEW YORK–(BUSINESS WIRE)–According to a new market research published by Persistence Market Research titled, “Global Market Study on Neurostimulation Devices: Deep Brain Stimulation Devices to Witness Highest Growth by 2020”, […]
